NO902995L - Stabilisert fgf sammensetning samt fremstilling derav. - Google Patents

Stabilisert fgf sammensetning samt fremstilling derav.

Info

Publication number
NO902995L
NO902995L NO90902995A NO902995A NO902995L NO 902995 L NO902995 L NO 902995L NO 90902995 A NO90902995 A NO 90902995A NO 902995 A NO902995 A NO 902995A NO 902995 L NO902995 L NO 902995L
Authority
NO
Norway
Prior art keywords
fgf protein
stabilized
composition
manufacturing
water
Prior art date
Application number
NO90902995A
Other languages
English (en)
Other versions
NO902995D0 (no
Inventor
Yohko Akiyama
Minoru Yoshioka
Nobuyuki Kitamori
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of NO902995D0 publication Critical patent/NO902995D0/no
Publication of NO902995L publication Critical patent/NO902995L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Fodder In General (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Transition And Organic Metals Composition Catalysts For Addition Polymerization (AREA)
NO90902995A 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav. NO902995L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP17622889 1989-07-07
JP13633390 1990-05-24

Publications (2)

Publication Number Publication Date
NO902995D0 NO902995D0 (no) 1990-07-04
NO902995L true NO902995L (no) 1991-01-08

Family

ID=26469955

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90902995A NO902995L (no) 1989-07-07 1990-07-04 Stabilisert fgf sammensetning samt fremstilling derav.

Country Status (14)

Country Link
US (1) US5189148A (no)
EP (1) EP0406856B1 (no)
JP (1) JP2536247B2 (no)
CN (1) CN1049106A (no)
AT (1) ATE102044T1 (no)
AU (1) AU632344B2 (no)
CA (1) CA2020654A1 (no)
DE (1) DE69006947T2 (no)
DK (1) DK0406856T3 (no)
ES (1) ES2062206T3 (no)
FI (1) FI903440A7 (no)
HU (1) HU205862B (no)
IE (1) IE902470A1 (no)
NO (1) NO902995L (no)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5763394A (en) * 1988-04-15 1998-06-09 Genentech, Inc. Human growth hormone aqueous formulation
US5202311A (en) * 1988-08-19 1993-04-13 Children's Medical Center Corporation Stabilized fgf composition
US5714458A (en) * 1990-07-18 1998-02-03 Farmitalia Carlo Erba S.R.L. Stable pharmaceutical compositions containing a fibroblast growth factor
GB9015824D0 (en) * 1990-07-18 1990-09-05 Erba Carlo Spa Stable pharmaceutical compositions containing a fibroblast growth factor
US5500409A (en) * 1990-10-01 1996-03-19 Thomas Jefferson University Method for inhibiting collagen synthesis by keloid fibroblasts
TW209174B (no) * 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
DK0590060T3 (da) 1991-06-21 1998-05-11 Univ Cincinnati Oralt indgivelige terapeutiske proteiner samt fremgangsmåde til fremstilling
US6613332B1 (en) 1991-06-21 2003-09-02 The University Of Cincinnati Oral administration of therapeutic proteins
DE4121043A1 (de) * 1991-06-26 1993-01-07 Merck Patent Gmbh Knochenersatzmaterial mit fgf
CA2080537A1 (en) * 1991-10-21 1993-04-22 David B. Volkin Stabilized topical acidic fibroblast growth factor formulation
CA2080538A1 (en) * 1991-10-21 1993-04-22 Joseph V. Bondi Lyophilized acidic fibroblast growth factor
US5580578A (en) * 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5482929A (en) * 1991-12-26 1996-01-09 Kaken Pharmaceutical Co., Ltd. Composition of stabilized fibroblast growth factor
US7070806B2 (en) * 1992-01-27 2006-07-04 Purdue Pharma Lp Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5348941A (en) * 1992-04-01 1994-09-20 Merck & Co., Inc. Stabilizers for fibroblast growth factors
SE9201073D0 (sv) * 1992-04-03 1992-04-03 Kabi Pharmacia Ab Protein formulation
DE4242889A1 (de) * 1992-12-18 1994-06-23 Merck Patent Gmbh Hohlendoprothesen mit Knochenwachstumsfördernder Füllung
JP3349535B2 (ja) * 1993-01-12 2002-11-25 フロイント産業株式会社 球形顆粒の製造方法
US5331095A (en) * 1993-04-12 1994-07-19 Scios Nova Inc. Process for purification of basic fibroblast growth factor
EP0702959B1 (en) * 1993-05-31 2001-08-08 Kaken Pharmaceutical Co., Ltd. Cross-linked gelatin gel preparation containing basic fibroblast growth factor
JPH07112940A (ja) * 1993-08-26 1995-05-02 Takeda Chem Ind Ltd 徐放性非経口投与製剤およびその製造方法
CN1228708A (zh) * 1996-09-04 1999-09-15 有限会社多特 经口给药用含肽药物组合物
US6692961B1 (en) * 1996-10-11 2004-02-17 Invitrogen Corporation Defined systems for epithelial cell culture and use thereof
US5851579A (en) * 1996-10-28 1998-12-22 Eastman Chemical Company Aqueous enteric coating compositions
DK1189523T3 (da) * 1999-06-07 2003-10-20 Fibersugar Aps Partikulær fibersammensætning
US20030228288A1 (en) 1999-10-15 2003-12-11 Scarborough Nelson L. Volume maintaining osteoinductive/osteoconductive compositions
CN1402629A (zh) 1999-12-23 2003-03-12 辉瑞产品公司 提供提高的药物浓度的药物组合物
JP4711520B2 (ja) * 2000-03-21 2011-06-29 日本ケミカルリサーチ株式会社 生理活性ペプチド含有粉末
US9387094B2 (en) 2000-07-19 2016-07-12 Warsaw Orthopedic, Inc. Osteoimplant and method of making same
US7323193B2 (en) 2001-12-14 2008-01-29 Osteotech, Inc. Method of making demineralized bone particles
US7163691B2 (en) * 2001-10-12 2007-01-16 Osteotech, Inc. Bone graft
FR2836011B1 (fr) * 2002-02-20 2004-05-14 Goemar Lab Sa Agent pour la stimulation des defenses naturelles des plantes et procede pour sa mise en oeuvre
US20050142076A1 (en) * 2002-04-01 2005-06-30 Kazuhiro Fukunaga Dental viscous pharmaceutical containing basic fibroblast growth factor
WO2004110308A2 (en) 2003-06-11 2004-12-23 Osteotech, Inc. Osteoimplants and methods for their manufacture
ES2396689T3 (es) 2003-12-11 2013-02-25 Isto Technologies Inc. Sistema de cartílago particulado
US20070003541A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for therapeutics
US20070004036A1 (en) * 2005-07-01 2007-01-04 Rodolfo Faudoa Methods and compositions for keratinocyte culture
US20070128685A1 (en) * 2005-07-01 2007-06-07 Rodolfo Faudoa Methods and compositions for cell culture
EP1916964A4 (en) 2005-08-26 2015-11-04 Zimmer Inc IMPLANTS AND METHODS FOR THE REPAIR, REPLACEMENT AND TREATMENT OF JOINT DISEASES
WO2007056671A1 (en) 2005-11-02 2007-05-18 Osteotech, Inc. Hemostatic bone graft
US8163549B2 (en) 2006-12-20 2012-04-24 Zimmer Orthobiologics, Inc. Method of obtaining viable small tissue particles and use for tissue repair
US20080154233A1 (en) * 2006-12-20 2008-06-26 Zimmer Orthobiologics, Inc. Apparatus for delivering a biocompatible material to a surgical site and method of using same
AU2008240191B2 (en) 2007-04-12 2013-09-19 Zimmer, Inc. Compositions and methods for tissue repair
JP2012506733A (ja) 2008-10-24 2012-03-22 ウォーソー・オーソペディック・インコーポレーテッド 骨形成を促進するための組成物および方法
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
WO2013147264A1 (ja) * 2012-03-30 2013-10-03 味の素株式会社 硫酸化化合物を含む幹細胞増殖用培地
US20140178343A1 (en) 2012-12-21 2014-06-26 Jian Q. Yao Supports and methods for promoting integration of cartilage tissue explants
PL3380508T3 (pl) 2015-11-27 2021-07-12 Masarykova Univerzita Termostabilny polipeptyd fgf2, jego zastosowanie
JP2021138648A (ja) * 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4183796A1 (en) 2021-11-19 2023-05-24 Enantis s.r.o. Thermostable fgf10 polypeptide or fragment thereof use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ235556A (en) * 1986-11-05 1991-06-25 Ethicon Inc Breast milk substitute containing recombinant human egf
US4717717A (en) * 1986-11-05 1988-01-05 Ethicon, Inc. Stabilized compositions containing epidermal growth factor
JP2526965B2 (ja) * 1987-02-24 1996-08-21 武田薬品工業株式会社 ムテイン，ｄｎａおよびその用途
NZ226170A (en) * 1987-09-18 1990-07-26 Ethicon Inc Stable freeze-dried pharmaceutical composition containing epidermal growth factor
NZ226171A (en) * 1987-09-18 1990-06-26 Ethicon Inc Gel formulation containing polypeptide growth factor

Also Published As

Publication number Publication date
HU205862B (en) 1992-07-28
ES2062206T3 (es) 1994-12-16
JPH04128239A (ja) 1992-04-28
CA2020654A1 (en) 1991-01-08
IE902470A1 (en) 1991-02-13
ATE102044T1 (de) 1994-03-15
EP0406856A3 (en) 1991-04-10
FI903440A7 (fi) 1991-01-08
HUT54895A (en) 1991-04-29
US5189148A (en) 1993-02-23
NO902995D0 (no) 1990-07-04
AU632344B2 (en) 1992-12-24
HU904116D0 (en) 1990-12-28
EP0406856B1 (en) 1994-03-02
AU5879990A (en) 1991-01-10
DK0406856T3 (da) 1994-07-04
CN1049106A (zh) 1991-02-13
FI903440A0 (fi) 1990-07-06
EP0406856A2 (en) 1991-01-09
DE69006947D1 (de) 1994-04-07
JP2536247B2 (ja) 1996-09-18
DE69006947T2 (de) 1994-08-25

Similar Documents

Publication Publication Date Title
NO902995L (no) Stabilisert fgf sammensetning samt fremstilling derav.
SE9002522L (sv) Metod foer framstaellning av en farmaceutisk komposition i form av mikropartiklar
ZA907338B (en) Thienylcarboxylates of amino alcohols
AU1470292A (en) Stabilized factor viii preparations
NO870890D0 (no) Fremgangsmaate for fremstilling av 2-aminoalkyl-1,2-benzoisothiazol-3(2h)on-1,1-dioxyd-derivater.
NO892217D0 (no) Manoevreringsanordning for lasteskuffe.
NO922953D0 (no) Rekombinant fremstilt blodfaktorer og fremgangsmaate for ekspresjon av blodfaktorene, samt vacciniavirusrekombinanter
ES2068919T3 (es) Preparaciones nematicidas.
ATE140962T1 (de) Dns-klone von menschlichem thrombomodulin
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
BG37376A3 (en) Method for preparing salts of benzothiazine dioxide
DE59006688D1 (de) Substituierte Aminosäureamid-Derivate, deren Herstellung und Verwendung.
DE3886936D1 (de) 2,5,6,7-TETRANOR-4,8-INTER-m-PHENYLEN 2-PGI-DERIVATE, VERFAHREN ZUR HERSTELLUNG UND DEREN VERWENDUNG.
EP0254239A3 (en) Optically pure 1,3-dioxenones, methods for preparing same and use thereof
DE69018816D1 (de) Aminosäurederivate.
ATE112264T1 (de) Verfahren zur herstellung von 2,6-di-t-butyl-4- merkaptophenol.
AU6764790A (en) 13-beta-phenethylthio-milbemycin derivatives
FI875787A7 (fi) Foerfarande foer framstaellning av lipofila aminosyraderivat, samt lipofila aminosyraderivat.
NO905244L (no) Fremgangsmaate for fremstilling av des(64,65)-proinsulin.
DE68903983D1 (de) 1,6-diazaspiro(4,4)nonan-2,7-dion-derivate.
DE69009651D1 (de) Verfahren zur Herstellung von 3,4-Dihydrocumarinderivaten.
SE8605535L (sv) Cellsystem, dess framstellning och anvendning
ATE80873T1 (de) Tetrahydropyridin-derivate.
IT8619653A0 (it) Procedimento per la produzione di bussole a struttura perfezionara, per l'unione di parti in legno.
ATE102207T1 (de) 1,1-dioxo-cephem-4-carbothiolsaeure-derivate.